[Treatment with Doxazosin in 3347 patients with lower urinary tract symptoms. Impact on sexual function. The impros study].
OBJECTIVE
An open, non-comparative, multicenter study was performed to ascertain the prevalence in Spain of erectile dysfunction (ED) associated to benign prostatic hypertrophy (BPH), with moderate to severe urinary symptoms, and to confirm the improvement or disappearance of ED in response to treatment with 4 mg/day of Doxazosin.


METHODS
Out of the 3901 patients recruited 3545 took the medication and 3347 completed all the protocol visits. BPH patients were considered to have some degree of erectile dysfunction when they reported a difficulty for obtaining and/or maintaining an erection in the four weeks prior to their inclusion in the study (questions 3 and 4 of the International Index of Erectile Function). All the patients were treated with Doxazosin at increasing doses: from 1 mg/day up to 4 mg/day thereafter until 6 months of medication were completed.


RESULTS
The mean number of patients showing erectile dysfunction was 69.1%, ranging from 48.3% in the 40-49 years age group to 76.3% in the group aged from 60 to 69 years. In most Spanish regions, the prevalence of ED ranged from 76.9% in Cantabria to 67.2% in Aragon. The mean number of patients in whom erectile dysfunction disappeared after treatment, with a 95% confidence interval, was 4.5%, ranging from 17.5% in the 40-49 age group to 1.1% in the over 70s.


CONCLUSIONS
ED is a symptom very often associated to BPH, even in relatively young men. Doxazosin appears to have a beneficial effect in ED improvement, particularly in the younger patients.
Hernández Fernández
C
C
Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid.
Moncada Iribarren
I
I
Jara Rascón
J
J
Castaño González
I
I
Moralejo Gárate
M
M
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017292:Doxazosin / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D017292:Doxazosin